Drotaverine-d10 (hydrochloride)

• UNSPSC Description:

  Drotaverine-d10 (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects[1][2].

• Target Antigen:

  Calcium Channel; Isotope-Labeled Compounds; Phosphodiesterase (PDE)

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;Others

• Field of Research:

  Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C([2H])(C([2H])([2H])[2H])OC1=CC2=C(C=C1OC([2H])(C([2H])([2H])[2H])[2H])CCN/C2=C\C3=CC=C(OCC)C(OCC)=C3.Cl

• Molecular Weight:

  444.03

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Patai Z, Guttman A, Mikus EG. Assessment of the Airway Smooth Muscle Relaxant Effect of Drotaverine. Pharmacology. 2018;101(3-4):163-169.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported